The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD).

The study drug will be administered intravenously (IV) (into a vein in the arm).

The study will last up to approximately 156 weeks, excluding screening.

Inclusion Criteria:

• A Telephone Interview for Cognitive Status - Modified (TICS-M) score indicative of intact cognitive function (cut-off score of 35 or higher)

• Clinical Dementia Rating-Global Score (CDR-GS) of 0

• A plasma P-tau result consistent with amyloid pathology

• A reliable study partner who:

  • Provides written informed consent to participate in the study in their role
  • Has frequent contact with the participant and is familiar with their overall function and behavior, including daily activities and cognitive abilities
  • Is of legal age (18 years of age or older) to consent
  • Is available to conduct functional scales

• Have adequate literacy, vision, and hearing for neuropsychological testing

Exclusion Criteria:

• Have mild cognitive impairment (MCI), dementia, or other significant neurodegenerative diseases that could affect cognition
• Have a serious or unstable illness (including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease, or other condition) that, in the investigator's opinion, could interfere with study analyses or result in a life expectancy of 5 years or fewer
• Have received active or passive immunization against amyloid beta (Aβ) in any other study
• Have current or prior use of prescription medications for treatment of MCI or AD
• Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants or other accessory medical devices, such as cardiac pacemakers, stents, and cochlear implants
• Have a centrally read magnetic resonance imaging (MRI) demonstrating the presence of Amyloid-related imaging abnormalities (ARIA-E), more than 4 cerebral microhemorrhages, more than 1 area of cortical superficial siderosis, any macrohemorrhage (that is, intracerebral hemorrhage more than 1 cm), or severe white matter disease at screening

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.